Breast cancer is the most common cancer in women, but its pathogenesis is still unclear. Microsatellite instability (MSI) has been identified in breast cancer cells, suggesting an association with mismatch repair defects. To test this hypothesis, we investigated MSI, protein expression of hMSH2 and hMLH1, as well as genetic and epigenetic modifications of these two genes in 32 sporadic breast tumors. MSI was identified in 15 cases. Immunohistochemistry analysis revealed that all MSI cases but one had lower than normal expression of hMSH2 (nine cases), hMLH1 (12 cases), or both (seven cases). In tumors with MSI, both genetic and epigenetic modifications of these mismatch repair genes were also identified. Eight cases harbored mutations or polymorphisms in hMSH2 and hMLH1, and 10 exhibited hypermethylation in the promoter region of hMLH1. These results suggest that both genetic and epigenetic alterations of hMSH2 and especially of hMLH1 contribute to genomic instability and tumorigenesis in sporadic breast cancer.
Introduction
Breast cancer is the most prevalent malignancy in women of Western industrialized countries. In the majority of cases, the cause of this disease is still unknown even though two breast cancer susceptibility genes (BRCA1 and BRCA2), mutated in approximately 5 -10% of all breast cancers, have been identified. Recent studies indicate that a substantial fraction of breast tumors have frequent microsatellite instability (MSI) (Aldaz et al., 1995; Contegiacomo et al., 1995; Cui et al., 1998; de Marchis et al., 1997; Fujii et al., 1998; Jonsson et al., 1995; Paulson et al., 1996; Rosenberg et al., 1997; Rush et al., 1997; Shaw et al., 1996; Shen et al., 2000; Siah et al., 2000; Toyama et al., 1996a,b; Walsh et al., 1998; Yee et al., 1994; Zenklusen et al., 1994) , a phenomenon tightly associated with mismatch repair (MMR) deficiency (Parsons et al., 1993; Strand et al., 1993) and initially observed in cells from hereditary non-polyposis colorectal cancers (HNPCC) as well as some sporadic colorectal tumors (Aaltonen et al., 1993; Thibodeau et al., 1993) . Defective MMR has also been identified in other types of cancer associated with MSI, including sporadic gastric (Bevilacqua and Simpson, 2000; Fleisher et al., 1999; Leung et al., 1999) and endometrial cancers (Esteller et al., 1998 Gurin et al., 1999; Katabuchi et al., 1995; Salvesen et al., 2000) . Although several human MMR genes are implicated in cancer predisposition, the hMSH2 and hMLH1 genes are the ones most often defective in MSI cancer cells (for reviews, see Kinzler and Vogelstein, 1996; Kolodner, 1995; Modrich and Lahue, 1996) .
Two major mechanisms by which MMR could be inactivated during carcinogenesis have been proposed. One mechanism involves epigenetic gene silencing by promoter hypermethylation; the other, genetic mutation in MMR genes (for reviews, see Baylin and Herman, 2000; Herman and Baylin, 2000; Kinzler and Vogelstein, 1996) . In the majority of sporadic colorectal and endometrial cancers with MSI, MMR appears to be inactivated by epigenetic gene silencing via hypermethylation of the hMLH1 promoter Esteller et al., 1998; Gurin et al., 1999; Kuismanen et al., 2000; Thibodeau et al., 1996) . Detailed mechanisms describing how genetic or epigenetic processes cause MMR deficiency and MSI in breast cancer are not yet known.
This study investigates protein expression, hypermethylation and genetic alterations of MMR genes, hMSH2 and hMLH1, and examines the correlation between these alterations and MSI in sporadic breast cancer. The results demonstrate that genetic and epigenetic modifications of these two MMR genes, especially hMLH1, are closely associated with MSI in breast tumors, suggesting that in some cases defects in MMR may contribute to development of this sporadic cancer.
Results

MSI in sporadic breast cancer
MSI was examined in 30 pairs of breast tumors and normal breast tissue. Samples were tested for instability with five microsatellite markers previously shown to be highly unstable in sporadic breast cancer: CHLC.GGAA4D07 (chr. 2, GGAA repeat), D8S135 (chr. 8, GA repeat); Mfd257 (chr. 11, CA repeat), ACTC (chr. 15, CA repeat), and GGAA2E02 (chr. 21, A and GGAA repeats) (Paulson et al., 1996; Yee et al., 1994) . Cases with two or more markers exhibiting instability and those with one such marker were categorized as high frequency MSI (MSI-H) and low frequency MSI (MSI-L), respectively (Boland et al., 1998; Thibodeau et al., 1998) . Cases with no unstable markers were classified as microsatellite stable (MSS). A clear difference in size of microsatellite bands between paired tumor and normal tissue from the same case was regarded as positive for instability. Stringent criteria previously established (Aaltonen et al., 1993) and implemented in several studies (Aaltonen et al., 1993; Liu et al., 1995; Paulson et al., 1996) were used for MSI analysis. Representative MSI gels are shown in Figure 1 and all instability data are summarized in Table 1 . Individual markers showed the following rates of instability: CHLC.GGAA4D07, 13.3%; D8S135, 16.7%; Mfd257, 16.7%; ACTC, 10%; and GGAA2E02, 20%. As shown in Table 1 , 6 (20%), 9 (30%), and 15 (50%) cases showed MSI-H, MSI-L, and MSS, respectively. These results indicate that a significant fraction of breast tumors tested in this study display MSI.
Reduced expression of hMSH2 and hMLH1 in breast tumors with MSI
The relationship between MSI and expression of hMSH2 and hMLH1 was examined in paired normal and tumor tissue from 32 cases of sporadic breast cancer using immunohistochemistry. In all cases, nonneoplastic cells showed strong nuclear staining with both the hMLH1 and hMSH2 antibodies. As summarized in Table 1 , nine cases (28.1%) showed reduced expression of hMSH2 (+to++), and 12 cases (37.5%) had reduced or no (two cases) expression of hMLH1 (7to++). In all cases, matching normal epithelial cells showed strong nuclear staining for hMLH1 (see Figure 2 for example) and hMSH2 (data not shown). The results indicate that MSI is significantly associated with reduced expression of these MMR proteins. In MSI-H and MSI-L cases, cancer cells exhibited reduced hMSH2 expression in three out of six (50%) and six out of nine cases (66.7%), respectively (P50.01); in contrast, cancer cells from MSS cases did not have reduced expression of hMSH2 (0/15 cases). This association between reduced protein expression and MSI was stronger for hMLH1. Cancer cells in cases with MSI-H and MSI-L had reduced expression of hMLH1 in five out of six (88.3%) and seven out of nine cases (77.8%), respectively (P50.001); no reduction in hMLH1 expression was detected in MSS cases (0/15 cases). It is notable that all MSI cases but one (case 15) expressed lower than normal levels of hMSH2 and/or hMLH1. In contrast, all 15 MSS cases expressed normal levels of both hMSH2 and hMLH1.
Mutations of hMSH2 and hMLH1 in sporadic breast cancer
The hMSH2 and hMLH1 genes were examined for sequence alterations that could result in reduced protein expression. Thirty-two cases were analysed by PCR -SSCP (Single Strand Conformational Polymorphism) performed on all coding exons, including all exon-intron boundaries and known splice sites of hMSH2 (16 exons) and hMLH1 (19 exons). Samples exhibiting altered migration during SSCP were sequenced. Representative results of SSCP and direct sequencing are shown in Figures 3 and 4 , respectively, and all alterations are listed in Table 1 . Case 9 (Figures 3a and 4a) had a nonsense mutation in exon 7 of (Figures 3b and 4b) showed a three-nucleotide (CTT) deletion in the 3' UTR (+32 nt) of hMLH1. Case 8 was found to harbor a missense mutation in exon 14 of hMLH1, converting Arg 522 to Leu 522 . It is conceivable that any of these alterations could affect protein expression. To our knowledge, these mutations have not been previously described. Missense mutations identified in exon 7 of hMSH2 (codon 387, Leu to Pro) in case 4 and in exon 9 of hMLH1 (codon 260, Leu to Phe) in case 15 did not appear to affect protein expression. Several heterozygous alterations were also found. Case 4 had a basepair substitution at the intron-exon boundary of hMLH1 intron 4, which could potentially affect splicing. A missense alteration detected in exon 8 of hMLH1 (codon 219, Ile to Val; cases 4 and 17), has been previously reported as a rare intragenic polymorphism in patients with HNPCC (Liu et al., 1995) .
Interestingly, all cases with mutations exhibited MSI-H or MSI-L phenotypes; in contrast no mutations were detected in these two MMR genes in MSS cases. One MSS case (case 17) did exhibit two polymorphisms. Of nine cases with attenuated hMSH2 immunoreactivity, only one had a mutation in hMSH2. On the other hand, four out of 12 cases with reduced expression of hMLH1 had mutations in hMLH1.
Promoter hypermethylation in sporadic breast cancer
Promoter hypermethylation of MMR genes is a major contributor to MMR deficiency in certain types of sporadic cancer Herman and Baylin, 2000) . Methylation-specific PCR (MSP) was performed to determine if hypermethylation of MMR gene promoters is associated with MSI and reduced MMR protein expression in breast cancer Figure 5 for example), showed that hypermethylation of the hMLH1 promoter was closely associated with MSI-H and MSI-L phenotypes. All MSI-H cases, except case 9, had hypermethylation in the hMLH1 promoter. Interestingly, these cases had reduced or no expression of hMLH1 (Table 1) . Ten out of 12 cases (83.3%) with reduced or no expression of hMLH1 exhibited promoter hypermethylation, whereas none of the cases with normal hMLH1 expression exhibited any hypermethylation (Table 1) . These results indicate that hypermethylation of the hMLH1 promoter is strongly Direct sequencing demonstrated a CAA to TAA (Gln to Stop) mutation in exon 7 of hMSH2 (a, case 9) indicated by arrows and a CTT deletion in the 3' UTR of hMLH1 (b, case 3) marked with an asterisk (*). T and N denote tumor and normal, respectively Figure 5 Methylation of the hMSH2 and hMLH1 promoter regions. MSP products were electrophoresed on agarose gels and visualized by ethidium bromide staining. Presence of a product in lanes marked 'U' and 'M' indicates the presence of unmethylated and methylated promoter sequences, respectively. Case numbers are indicated above gel lanes. DNA from normal lymphocytes (L) was used as a positive control for unmethylated sequences in the hMSH2 and hMLH1 promoter regions. In vitro-methylated DNA from lymphocytes (M) was used as a positive control for methylated promoter regions. The endometrial cancer cell line AN 3 CA (E) was also used as a positive control for methylated hMLH1 promoter sequences (Kane et al., 1997) correlated with decreased hMLH1 protein expression (P50.000001) in sporadic breast cancers with MSI.
In contrast, hypermethylation of the promoter of hMSH2 was detected in only one case (case 13, Figure  5 and Table 1 ), in which the expression of hMSH2 was only slightly attenuated. Thus, it is likely that the mechanism by which hMSH2 expression is reduced in MSI breast cancer cells does not involve epigenetic gene silencing.
Discussion
The status of MMR genes has been extensively studied in colorectal cancer cells, but the involvement of the MMR system is poorly studied and understood in breast cancer cells. However, given the association of breast cancer with MSI, it is likely that loss of MMR function could be responsible for the mutator phenotype observed in some breast tumors. Indeed, this study demonstrates a close link between MSI and lost or decreased expression of hMSH2 and hMLH1 in breast tumors. Genetic alterations or epigenetic modifications of hMSH2 or hMLH1 were identified in a majority of tumors with MSI and abnormal expression of hMSH2 or hMLH1.
As stated above, MSI, initially identified as a phenomenon associated with HNPCC and a subset of sporadic colorectal cancers (Aaltonen et al., 1993; Thibodeau et al., 1993) , has also been subsequently observed in many types of sporadic cancers (for review, see Eshleman and Markowitz, 1995), including sporadic breast cancer. However, the reported rates of MSI in sporadic breast cancer vary greatly (Aldaz et al., 1995; Contegiacomo et al., 1995; Cui et al., 1998; de Marchis et al., 1997; Fujii et al., 1998; Jonsson et al., 1995; Paulson et al., 1996; Rosenberg et al., 1997; Rush et al., 1997; Shaw et al., 1996; Shen et al., 2000; Siah et al., 2000; Toyama et al., 1996a,b; Walsh et al., 1998; Yee et al., 1994; Zenklusen et al., 1994) , possibly due to differences in the degree of cancer progression and in the methods and markers used for analysis. Using five markers previously shown to be highly unstable in breast cancer (Paulson et al., 1996; Yee et al., 1994) , we observed a relatively high mutation rate for each marker (from 10 to 20%). Since these markers contain different repeat units, the results indicate that MSI rates in breast cancer may not be dependent on the size or type of the repeat unit.
This study showed that only a fraction of sporadic breast cancer cases had mutations in hMSH2 and hMLH1; in contrast, these genes were frequently mutated in other cancers Esteller et al., 1998; Gurin et al., 1999; Katabuchi et al., 1995; Kuismanen et al., 2000; Thibodeau et al., 1996) . Mutations in hMSH2 were observed in exons 7 and 13 in sporadic breast cancer tissue. These sites were previously reported to be two of the most frequently mutated regions of hMSH2 associated with HNPCC, with exons 7 and 13 being the second and fourth most commonly altered regions, respectively (Weber et al., 1997) . On the other hand, more mutations in hMLH1 than in hMSH2 were detected in sporadic breast cancer tissue. No 'hot spots' or frequently mutated exons were identified in hMLH1, which is also consistent with previous studies in HNPCC patients (Weber et al., 1997) . Potential polymorphisms were also observed in this study. However, given the number of cases, appropriate evaluation of polymorphisms and their contributions to disease was not feasible.
It is worth noting that in this study, MMR function was assessed by immunohistochemistry, which may underestimate loss of MMR protein function since expressed nonfunctional proteins may not exhibit a concomitant decrease in immunoreactivity. Thus, protein expression would be detected in cells defective in MMR. Also, some mutations may not have been detected because of the limited sensitivity of SSCP. Nevertheless, the results indicate that gene mutations may not be the major cause for loss of MMR function in sporadic breast cancer.
This study showed that MSI is significantly associated with reduced expression of hMLH1 and with hypermethylation of the hMLH1 promoter. Also, hypermethylation of the hMLH1 promoter was detected in 10 out of 12 breast tumors with reduced or no expression of hMLH1 (Table 1) . These results indicate that, as in sporadic colorectal, gastric and endometrial cancers, the mutator phenotype in breast tumors can also be caused by hypermethylation of the hMLH1 promoter. Only one case with hypermethylation of the hMSH2 promoter was observed. This case also had reduced hMSH2 protein expression. Previous studies on colorectal and endometrial cancers demonstrated that hypermethylation of the hMSH2 promoter seemed to occur only in familial Salvesen et al., 2000) , but not in sporadic cases Esteller et al., 1998 Esteller et al., , 1999 . Our results are consistent with those previous observations in that hypermethylation of the hMSH2 promoter is rare in sporadic breast cancer.
In summary, we have demonstrated that alterations of hMLH1 and hMSH2 are correlated with MSI in sporadic breast cancer. Genetic and epigenetic alterations in these two genes are likely to diminish MMR function, increase mutations in oncogenes and tumor suppressor genes, and facilitate carcinogenesis. Although both hMSH2 and hMLH1 contribute to this process, our data suggest that inactivation of hMLH1 is more strongly correlated with a mutator phenotype than hMSH2, and that epigenetic modification, rather than mutation, is likely to be a common mechanism for eliminating hMLH1 protein inactivity in sporadic breast cancer. These findings show that MMR defects are not only important in sporadic cancers with familial counterparts observed in HNPCC whether or not breast cancer is part of the tumor spectrum of HNPCC is controversial (Scott et al., 2001; Vasen et al., 2001; Lynch and de la Chapelle, 1999) but, as has recently also been reported by others for leukemia and prostate cancer (Hangaishi et al., 1997; Hosoya et al., 1998; Levati et al., 1998) , it can play a role in the progression of certain sporadic cancers with no familial manifestation in HNPCC.
Materials and methods
Sample collection and DNA isolation
Archival, paraffin-embedded sections of paired sporadic breast cancer and normal tissue were obtained for 32 cases from the Tissue Procurement Service at the University of Kentucky Hospital. DNA was isolated as previously described (Thibodeau et al., 1996 .
Microsatellite instability
Five microsatellite markers (CHLC.GGAA4D07, D8S135, Mfd257, ACTC, and GGAA2E02) were examined by standard PCR technique to determine MSI status in 30 paired breast cancer cases. PCR sense primers were endlabeled with [g-32 P]-ATP using T4 polynucleotide kinase (USB Corp., Cleveland, OH, USA) prior to their inclusion in PCR. Final products were analysed by electrophoresis on 6% denaturing polyacrylamide gels and detected by autoradiography.
Immunohistochemistry
Archival paraffin-embedded sections (5 mM) from 32 cases were deparaffinized with Hemo-De TM (Fisher Scientific, Pittsburgh, PA, USA) and rehydrated with graded ethanol. Antigen was retrieved by a heat-induced epitope retrieval method as described (Thibodeau et al., 1996 . Sections were incubated with mouse monoclonal antibodies against hMSH2 (Oncogene Science, Cambridge, MA, USA; clone FE11) or hMLH1 (PharMingen, San Diego, CA, USA; clone G168-15). Antibody specificity was determined by inhibiting nuclear staining of normal tissue sections after pre-incubation of antibodies with purified hMutSa (hMSH2-hMSH6) or hMutLa (hMLH1-hPMS2), which were purified as described (Li and Modrich, 1995; Li et al., 1996) . Immunoperoxidase staining was performed using diaminobenzidine and sections were counterstained with hematoxylin. Slides treated with horse serum instead of monoclonal antibodies were used as a negative control. On some slides, mononuclear cells were also used as a negative internal control.
Staining of tumor nuclei was evaluated without access to sample identification (i.e., blind). Semiquantitative analysis of immunoreactivity was performed as described (Friedrich et al., 1999) . A score of 0 to 3 for staining intensity was assigned as follows: 0 (no staining), 1 (weak but detectable), 2 (distinct), and 3 (strong). The percentage of positive tumor cells was assessed for each staining intensity level and given a percentage score: 1, 0 -10%; 2, 11 -50%; 3, 51 -80%; and 4, 81 -100%. Immunoreactive score was calculated by multiplying the percentage of positive staining cells by the intensity score, and assigned: 0 -1=no staining (7); 2 -3=very weak staining (+); 4 -6=weak staining (++); 8 -12=strong staining (+++).
PCR-single strand conformational polymorphism and DNA sequencing PCR primers to amplify all exons and flanking splice sites of hMSH2 and hMLH1 were synthesized using reported sequences (Weber et al., 1997) . PCR was performed as described above but labeling was with [a-32 P]-dCTP. PCR products were denatured, fractionated through 0.56MDE gels (BioWhittaker Molecular Applications, Rockland, ME, USA) without or with 5 or 10% glycerol, and visualized by autoradiography. Variant and wild type PCR products were excised and eluted from SSCP gels, and then reamplified omitting radiolabeled dCTP. Finally, the PCR products thus obtained were purified from agarose gels (Qiaquick, Qiagen, Valencia, CA, USA) and direct-sequenced using T7 Sequenase, version 2.0 DNA sequencing kit (USB Corp., Cleveland, OH, USA).
Methylation-specific PCR
DNA methylation in hMSH2 and hMLH1 promoter regions was assessed by methylation-specific PCR (MSP). MSP distinguishes methylated from unmethylated alleles based on sequence changes produced by sodium bisulfite modification, which converts unmethylated cytosine but not methylated cytosine to uracil (Frommer et al., 1992) . PCR primers were designed to anneal to methylated or unmethylated DNA and selectively amplify the methylated or unmethylated target DNA. DNA was modified with sodium bisulfite as described (Herman et al., 1996) . Lymphocyte DNA from normal volunteers was methylated in vitro at all CpG sites using excess SssI methyltransferase (New England Biolabs, Beverly, MA, USA) and was used as a positive control (Salvesen et al., 2000) . Untreated lymphocyte DNA was used as a control for unmethylated DNA.
MSP primers were designed to amplify the 'C' region (7248 to 7178 relative to the transcription start) of the hMLH1 promoter (Deng et al., 1999; Grady et al., 2001) using nested PCR. This region of the promoter was chosen because it had previously been shown that methylation in this region was more closely associated with transcriptional inactivation of hMLH1 than other regions of the promoter. In the first amplification, bisulfite modified DNA was amplified with PCR primers designed to specifically amplify bisulfite-modified DNA, but not native DNA, regardless of methylation status. Primers used were (sense) 5'-GGTATTTTTGTTTTTATTGGTTGGAT-3', and (antisense) 5'-AATACCAATCAAATTTCTCAA-CTCCT-3'. The product (7318 to 7133) of this reaction was used as a template in reactions that specifically amplify methylated or unmethylated sequences. The primers for methylated sequences were (sense) 5'-TAA-AAACGAATTAATAGGAAGAGC-3', and (antisense) 5'-CTCTATAAATTACTAAATCTCTTCG-3', and for unmethylated sequences were (sense) 5'-TAAAAATGAAT-TAATAGGAAGAGT-3', and (antisense) 5'-CTCTATAA-ATTACTAAATCTCTTCA-3' (7271 to 7154). MSP for the hMSH2 promoter region was performed as described for the hMLH1 promoter. The first PCR primers were (sense) 5'-(C/T)GTAGTTTTGGAAGTTGATTG-3' and (antisense) 5'-ACTTCTCC(A/G)ACATACCCTAA-3'. The nested primers for the second PCR were as previously described . PCR products were electrophoresed on agarose gels, stained with ethidium bromide and visualized with UV light.
Statistical analysis
Chi-square test and Fisher's exact test were used for analysis of statistical significance. P50.01 was designated as significant.
